Teleflex (TFX) to Release Earnings on Thursday

Teleflex (NYSE:TFX) is projected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $1.28 per share and revenue of $559.0410 million for the quarter. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. During the same quarter in the prior year, the firm posted $1.44 earnings per share. Teleflex’s quarterly revenue was up 32.3% on a year-over-year basis. On average, analysts expect Teleflex to post $7 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Teleflex Price Performance

Shares of TFX stock opened at $135.24 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The company has a market capitalization of $5.99 billion, a PE ratio of -5.93, a price-to-earnings-growth ratio of 1.00 and a beta of 0.82. The firm’s 50-day moving average is $130.79 and its two-hundred day moving average is $120.74. Teleflex has a 12 month low of $100.18 and a 12 month high of $139.67.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, May 22nd. Teleflex’s payout ratio is presently -5.96%.

Analysts Set New Price Targets

A number of research firms recently commented on TFX. Mizuho upped their price objective on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. BMO Capital Markets initiated coverage on Teleflex in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price target on the stock. Raymond James Financial reiterated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a report on Friday, May 8th. Finally, Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $148.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TFX. AQR Capital Management LLC increased its holdings in Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Teleflex by 123.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 660,800 shares of the medical technology company’s stock valued at $80,855,000 after buying an additional 365,663 shares during the period. Gumshoe Capital Management LLC acquired a new position in shares of Teleflex during the fourth quarter worth about $31,432,000. Integral Health Asset Management LLC acquired a new position in shares of Teleflex during the fourth quarter worth about $30,510,000. Finally, Walleye Capital LLC increased its stake in shares of Teleflex by 270.8% during the fourth quarter. Walleye Capital LLC now owns 319,168 shares of the medical technology company’s stock worth $38,951,000 after buying an additional 233,102 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.